According to a recent study, the bulk of the long-term effects patients experienced months after obtaining COVID-19 are greatly reduced by receiving at least two doses of Pfizer vaccines.
Among this study, eight of the ten most frequently reported symptoms were reported between 50% and 80% less frequently in individuals who got at least two doses of the COVID-19 immunisation as opposed to those who did not. The study, which was just published in the Nature journal npj Vaccines, was headed by Professor Michael Edelstein of the Azrieli Faculty of Medicine at Bar-Ilan University. At three of the Faculty’s associated hospitals in northern Israel, Baruch Padeh Medical Center, Ziv Medical Center, and Galilee Medical Center, he collaborated with the IT and infectious disease teams.
Of the 2,447 individuals who reported having no past illnesses, 21 (0.9%) had only had one dose, 1,195 (48.8%) had received two doses, 744 (30.4%) had received three doses, and 19.9% had not received any immunizations.
Comparisons were made between those who had gotten vaccines and those who had not regarding post-acute self-reported symptoms. They found that having two or more doses of the Pfizer vaccine was associated with a decreased likelihood of reporting the most common post-COVID symptoms after accounting for age and the interval between infection and survey participation. Participants in the current trial saw reductions in the most frequently reported symptoms, including fatigue, headaches, limb weakness, and persistent muscle pain, by 62%, 50%, 62%, and 66%, respectively. Breathlessness decreased by 80% and chronic muscular pain by 70%.
The study expands on the scant information currently known about how vaccinations affect long-term COVID. Prof. Michael Edelstein of the Azrieli Faculty at Bar-Ilan University, the study’s lead investigator, adds that “we don’t fully understand what occurs in the months and years following COVID-19 in terms of physical and mental health and welfare.” “We felt it was vital to investigate whether vaccinations could help treat the symptoms of extended COVID because it seems to afflict so many people. It is becoming more and more obvious that vaccinations offer defence not only against infectious diseases, but also against other diseases.
The degree of protection offered by immunizations against prolonged COVID is less well understood. In order to determine how vaccinations impact long-term quality of life, various COVID variants, and long-COVID symptoms, Edelstein has begun a series of studies that will follow a substantial cohort of individuals from all elements of Israel’s varied population.